Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Y Takeda

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Molecular Cell|August 7, 2018
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate OncogenesisGabriel J Sandoval, John L Pulice, Hubert Pakula, et al.
Cell|June 19, 2018
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate CancerDavid Y Takeda, Sándor Spisák, Ji-Heui Seo, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Cancer Research|December 9, 2024
Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate CancerJoonatan Sipola, Aslı D Munzur, Edmond M Kwan, et al.
The Prostate|January 27, 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samplesElizabeth H Stover, Coyin Oh, Paula Keskula, et al.
Cell Reports|February 23, 2022
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancerStephen Tang, Vidyalakshmi Sethunath, Nebiyou Y Metaferia, et al.
Nature Genetics|September 19, 2018
Mutational processes shape the landscape of TP53 mutations in human cancerAndrew O Giacomelli, Xiaoping Yang, Robert E Lintner, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Nature Communications|March 31, 2021
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSylvan C Baca, David Y Takeda, Ji-Heui Seo, et al.
Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Molecular Cell|August 7, 2018
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate OncogenesisGabriel J Sandoval, John L Pulice, Hubert Pakula, et al.
Cell|June 19, 2018
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate CancerDavid Y Takeda, Sándor Spisák, Ji-Heui Seo, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Cancer Research|December 9, 2024
Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate CancerJoonatan Sipola, Aslı D Munzur, Edmond M Kwan, et al.
The Prostate|January 27, 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samplesElizabeth H Stover, Coyin Oh, Paula Keskula, et al.
Cell Reports|February 23, 2022
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancerStephen Tang, Vidyalakshmi Sethunath, Nebiyou Y Metaferia, et al.
Nature Genetics|September 19, 2018
Mutational processes shape the landscape of TP53 mutations in human cancerAndrew O Giacomelli, Xiaoping Yang, Robert E Lintner, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Nature Communications|March 31, 2021
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSylvan C Baca, David Y Takeda, Ji-Heui Seo, et al.
Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
Pageof 3